Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
2021
In indolent non-Hodgkin’s lymphoma (iNHL), patients treated with rituximab, alone or in combination with various chemotherapeutic agents eventually relapse. This study evaluated the combination of ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
1
Citations
NaN
KQI